HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Disc Medicine (NASDAQ:IRON) and maintained a $70 price target.
June 14, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Disc Medicine (NASDAQ:IRON) and maintained a $70 price target.
The reiteration of a Buy rating and the maintenance of a $70 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100